阿斯利康退出CNS,释放的两个信号

医药时间
08 May

在资本与科学的博弈中,没有永恒的赛道,只有永恒的权衡。阿斯利康在一季度财报电话会议上对外宣布,全面退出神经科学(CNS)领域,将资源转向肿瘤、代谢疾病等核心赛道。这不是一场孤立的选择。过去十年,辉瑞、安进、默沙东等20余家药企相继缩减或撤离CNS战场,渤健等坚守者也正在拓展其他领域。尽管近年来新的突破不断,然而CNS的高风险与长周期,正在让药企与资本的耐心逐渐耗尽。在逐利的商业世界里,即使财力雄厚...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10